Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients

Lee, Andrew; Pike, James; Edwards, Michael; Petrillo, Jennifer; Waller, John; Jones, Eddie

doi:10.1007/s40120-016-0061-5

Cited by 13 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current treatment duration was at least 12 months. In the DMF group ( n = 31), the estimated average treatment effect for the HAQUAMS total score was −0.45 (95% CI −0.61 to −0.29) vs. 1.95 (95% CI 1.86–2.04) in patients receiving INFβ or GA ( n = 229; p < 0.001), and 0.075 (95% CI 0.014–0.136) vs. 0.823 (95% CI 0.793–0.852) [ p = 0.016] for the EQ-5D index [85]. …”

Section: Impact Of Dmds On Health-related Quality Of Lifementioning

confidence: 99%

Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

Jongen

2017

CNS Drugs

View full text Add to dashboard Cite

Multiple sclerosis (MS) has a profound impact on health-related quality of life (HRQoL), a comprehensive subjective measure of the patient’s health status. Assessment of HRQoL informs on the potential advantages and disadvantages of disease-modifying drugs (DMDs) beyond their effects on observer-based disability and magnetic resonance imaging abnormalities. This article reviews published data from randomized controlled trials and observational studies regarding the effects of currently available DMDs on HRQoL. Data indicate that DMD treatment is associated with prevention of worsening or with improvement of HRQoL, and that, in general, second-line DMDs may have a greater impact on HRQoL than first-line DMDs. In clinical practice, monitoring of HRQoL provides clinicians with unique information regarding disease impact and potential benefits and adverse effects of DMD treatment that may not be obtained otherwise; it might also permit early detection of an unfavorable disease course. It is suggested to assess HRQoL at the time of diagnosis and before starting or switching DMD treatment. Regular HRQoL measurements contribute to a comprehensive clinical evaluation, and may help to elucidate and quantify the patient’s contribution to shared decision making regarding DMD treatment. Further studies are needed to better determine the role of HRQoL assessments in daily MS care.

show abstract

Section: Impact Of Dmds On Health-related Quality Of Lifementioning

confidence: 99%

Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

Jongen

2017

CNS Drugs

View full text Add to dashboard Cite

show abstract

“…Patients treated with DMF also demonstrated better HRQoL assessment based upon reported improvement in The Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HAQUAMS)43 and EQ-5D. Regression analysis between HRQoL and WPAI-MS results further indicated that better quality of life was associated with improvement in work productivity 42. It is important to note that there were only thirty-one DMF patients in the Adelphi database, which significantly limits the conclusions that can be drawn from this analysis.…”

Section: Existing Literature On Dimethyl Fumarate and Prosmentioning

confidence: 90%

“…A cross-sectional study was performed which compared work productivity outcomes and HRQoL in PwMS who initiated on DMF with those taking other DMTs; specifically, interferon beta 1a, 1b or GA 42. The data was pulled from Adelphi MS Disease Specific Programme, a multinational cross-sectional study with 2965 RRMS and 494 SPMS patients 42. Thirty-one patients from the DMF treatment group and 229 patients from the other therapies group who completed at least one WPAI-MS assessment or an HRQoL measurement were included in this study.…”

Section: Existing Literature On Dimethyl Fumarate and Prosmentioning

confidence: 99%

<p>Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives</p>

Ozel

Vaughn

Eckert

et al. 2019

PROM

View full text Add to dashboard Cite

Dimethyl fumarate (DMF) is a commonly prescribed oral medication for the treatment of relapsing forms of multiple sclerosis (MS) with a wide range of hypothesized downstream mechanisms of action. Randomized clinical trials have established its clinical efficacy by using standard objective clinical measures. However, MS is a chronic disease that, apart from physical ailments, can affect an individual’s mood, psychosocial status, and quality of life which cannot be captured by using only objective assessment tools. Given the challenge of determining the efficacy of the treatment in a real-world clinical setting, the use of patient-reported outcomes (PROs) may help us to better address these aspects of patient care and establish a more patient-centered approach to MS care. To date, a review of PubMed identified six studies which reported on PROs in patients who are taking DMF. In total, twelve different kinds of PRO measures were utilized and 6359 patients provided at least one form of PRO in these studies. Upon review of these studies, we were able to conclude that people with MS had decreased quality of life compared to the healthy population in the US. MS patients on DMF, however, had better health-related quality of life assessment scores compared to those using a placebo. Previous studies also suggested that DMF decreased work productivity impairment scores after one year of use compared to baseline. DMF was associated with less impairment in fatigue and depression scales along with improved treatment quality assessment and adherence scores. This review will present a brief synopsis of the published literature and will provide indications for future directions with respect to PROs and DMF in people with MS.

show abstract

“…Dimethyl fumarate has been compared with a number of alternative treatments using CE research methods, including claims-based analyses [7, 8], a cross-sectional study [9], and a number of PSM analyses based on registries [10–14]. In the PSM analyses performed to date, DMF showed improved clinical effectiveness in terms of reductions in ARR and time to first relapse (TTFR) events versus IFN, GA, and TERI [13, 14], and a similar rate of relapse as FTY [10–12, 14].…”

Section: Introductionmentioning

confidence: 99%

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

et al. 2018

View full text Add to dashboard Cite

BackgroundComparative effectiveness (CE) research allows real-world treatment comparisons using outcome measurements important to physicians/patients. This German NeuroTransData registry-based analysis compared delayed-release dimethyl fumarate (DMF) effectiveness with interferons (IFN), glatiramer acetate (GA), teriflunomide (TERI), or fingolimod (FTY) in patients with relapsing–remitting multiple sclerosis (RRMS) using propensity score matching (PSM).MethodsData from registry patients aged ≥ 18 years with RRMS, ≥ 1 relapse, and Expanded Disability Status Scale (EDSS) assessment(s) after index therapy initiation underwent 1:1 PSM to match DMF with comparator populations baseline characteristics. Primary outcome measurement was time to first relapse (TTFR). Secondary outcome measurements included annualised relapse rate (ARR), proportion of patients relapse free at 12 and 24 months, time to index therapy discontinuation (TTD), and reasons for discontinuation. Exploratory analyses included time to 3- and 6-month EDSS confirmed disability progression (CDP). Non-pairwise censoring was the primary analysis method; pairwise censoring was the main sensitivity analysis method.FindingsPost-matched cohorts were well-balanced. By non-pairwise censoring, TTFR and ARR were significantly lower in DMF populations versus matched IFN, GA, and TERI, but there was no evidence of difference between DMF and FTY. TTD was similar between DMF and IFN, GA, and TERI, but significantly shorter versus FTY. Time to CDP generally showed no evidence of difference between DMF and comparator populations. Pairwise censored analysis results confirmed the non-pairwise censoring results.InterpretationThese results support previous CE studies in demonstrating relative improvement in real-world effectiveness with DMF versus first-line agents IFN, GA, and TERI, and similar effectiveness versus FTY.Electronic supplementary materialThe online version of this article (10.1007/s00415-018-9083-5) contains supplementary material, which is available to authorized users.

show abstract

Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients

Cited by 13 publications

References 27 publications

Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

<p>Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives</p>

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

Contact Info

Product

Resources

About